Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY)

Two randomised trials

Paul W. Noble, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Marilyn K Glassberg Csete, David Kardatzke, Talmadge E. King, Lisa Lancaster, Steven A. Sahn, Javier Szwarcberg, Dominique Valeyre, Roland M. Du Bois

Research output: Contribution to journalArticle

962 Citations (Scopus)

Abstract

Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was designed to confirm the results of a phase 2 study that suggested that pirfenidone, a novel antifibrotic and anti-inflammatory drug, reduces deterioration in lung function in patients with idiopathic pulmonary fibrosis. Methods In two concurrent trials (004 and 006), patients (aged 40-80 years) with idiopathic pulmonary fibrosis were randomly assigned to oral pirfenidone or placebo for a minimum of 72 weeks in 110 centres in Australia, Europe, and North America. In study 004, patients were assigned in a 2:1:2 ratio to pirfenidone 2403 mg/day, pirfenidone 1197 mg/day, or placebo; in study 006, patients were assigned in a 1:1 ratio to pirfenidone 2403 mg/day or placebo. The randomisation code (permuted block design) was computer generated and stratified by region. All study personnel were masked to treatment group assignment until after final database lock. Treatments were administered orally, 801 mg or 399 mg three times a day. The primary endpoint was change in percentage predicted forced vital capacity (FVC) at week 72. Analysis was by intention to treat. The studies are registered with ClinicalTrials.gov, numbers NCT00287729 and NCT00287716. Findings In study 004, 174 of 435 patients were assigned to pirfenidone 2403 mg/day, 87 to pirfenidone 1197 mg/day, and 174 to placebo. In study 006, 171 of 344 patients were assigned to pirfenidone 2403 mg/day, and 173 to placebo. All patients in both studies were analysed. In study 004, pirfenidone reduced decline in FVC (p=0•001). Mean FVC change at week 72 was -8•0% (SD 16•5) in the pirfenidone 2403 mg/day group and -12•4% (18•5) in the placebo group (diff erence 4•4%, 95% CI 0•7 to 9•1); 35 (20%) of 174 versus 60 (35%) of 174 patients, respectively, had a decline of at least 10%. A significant treatment eff ect was noted at all timepoints from week 24 and in an analysis over all study timepoints (p=0•0007). Mean change in percentage FVC in the pirfenidone 1197 mg/day group was intermediate to that in the pirfenidone 2403 mg/day and placebo groups. In study 006, the diff erence between groups in FVC change at week 72 was not significant (p=0•501). Mean change in FVC at week 72 was -9•0% (SD 19•6) in the pirfenidone group and -9•6% (19•1) in the placebo group, and the diff erence between groups in predicted FVC change at week 72 was not significant (0•6%, -3•5 to 4•7); however, a consistent pirfenidone eff ect was apparent until week 48 (p=0•005) and in an analysis of all study timepoints (p=0•007). Patients in the pirfenidone 2403 mg/day group had higher incidences of nausea (125 [36%] of 345 vs 60 [17%] of 347), dyspepsia (66 [19%] vs 26 [7%]), vomiting (47 [14%] vs 15 [4%]), anorexia (37 [11%] vs 13 [4%]), photosensitivity (42 [12%] vs 6 [2%]), rash (111 [32%] vs 40 [12%]), and dizziness (63 [18%] vs 35 [10%]) than did those in the placebo group. Fewer overall deaths (19 [6%] vs 29 [8%]) and fewer deaths related to idiopathic pulmonary fibrosis (12 [3%] vs 25 [7%]) occurred in the pirfenidone 2403 mg/day groups than in the placebo groups. Interpretation The data show pirfenidone has a favourable benefit risk profile and represents an appropriate treatment option for patients with idiopathic pulmonary fibrosis.

Original languageEnglish
Pages (from-to)1760-1769
Number of pages10
JournalThe Lancet
Volume377
Issue number9779
DOIs
StatePublished - May 21 2011

Fingerprint

Idiopathic Pulmonary Fibrosis
Vital Capacity
Placebos
pirfenidone
Lung
Intention to Treat Analysis
Dyspepsia
Anorexia
Dizziness

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg Csete, M. K., Kardatzke, D., ... Du Bois, R. M. (2011). Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. The Lancet, 377(9779), 1760-1769. https://doi.org/10.1016/S0140-6736(11)60405-4

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY) : Two randomised trials. / Noble, Paul W.; Albera, Carlo; Bradford, Williamson Z.; Costabel, Ulrich; Glassberg Csete, Marilyn K; Kardatzke, David; King, Talmadge E.; Lancaster, Lisa; Sahn, Steven A.; Szwarcberg, Javier; Valeyre, Dominique; Du Bois, Roland M.

In: The Lancet, Vol. 377, No. 9779, 21.05.2011, p. 1760-1769.

Research output: Contribution to journalArticle

Noble, PW, Albera, C, Bradford, WZ, Costabel, U, Glassberg Csete, MK, Kardatzke, D, King, TE, Lancaster, L, Sahn, SA, Szwarcberg, J, Valeyre, D & Du Bois, RM 2011, 'Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials', The Lancet, vol. 377, no. 9779, pp. 1760-1769. https://doi.org/10.1016/S0140-6736(11)60405-4
Noble, Paul W. ; Albera, Carlo ; Bradford, Williamson Z. ; Costabel, Ulrich ; Glassberg Csete, Marilyn K ; Kardatzke, David ; King, Talmadge E. ; Lancaster, Lisa ; Sahn, Steven A. ; Szwarcberg, Javier ; Valeyre, Dominique ; Du Bois, Roland M. / Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY) : Two randomised trials. In: The Lancet. 2011 ; Vol. 377, No. 9779. pp. 1760-1769.
@article{81b39d52fae44add928f4d69521b6af2,
title = "Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials",
abstract = "Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was designed to confirm the results of a phase 2 study that suggested that pirfenidone, a novel antifibrotic and anti-inflammatory drug, reduces deterioration in lung function in patients with idiopathic pulmonary fibrosis. Methods In two concurrent trials (004 and 006), patients (aged 40-80 years) with idiopathic pulmonary fibrosis were randomly assigned to oral pirfenidone or placebo for a minimum of 72 weeks in 110 centres in Australia, Europe, and North America. In study 004, patients were assigned in a 2:1:2 ratio to pirfenidone 2403 mg/day, pirfenidone 1197 mg/day, or placebo; in study 006, patients were assigned in a 1:1 ratio to pirfenidone 2403 mg/day or placebo. The randomisation code (permuted block design) was computer generated and stratified by region. All study personnel were masked to treatment group assignment until after final database lock. Treatments were administered orally, 801 mg or 399 mg three times a day. The primary endpoint was change in percentage predicted forced vital capacity (FVC) at week 72. Analysis was by intention to treat. The studies are registered with ClinicalTrials.gov, numbers NCT00287729 and NCT00287716. Findings In study 004, 174 of 435 patients were assigned to pirfenidone 2403 mg/day, 87 to pirfenidone 1197 mg/day, and 174 to placebo. In study 006, 171 of 344 patients were assigned to pirfenidone 2403 mg/day, and 173 to placebo. All patients in both studies were analysed. In study 004, pirfenidone reduced decline in FVC (p=0•001). Mean FVC change at week 72 was -8•0{\%} (SD 16•5) in the pirfenidone 2403 mg/day group and -12•4{\%} (18•5) in the placebo group (diff erence 4•4{\%}, 95{\%} CI 0•7 to 9•1); 35 (20{\%}) of 174 versus 60 (35{\%}) of 174 patients, respectively, had a decline of at least 10{\%}. A significant treatment eff ect was noted at all timepoints from week 24 and in an analysis over all study timepoints (p=0•0007). Mean change in percentage FVC in the pirfenidone 1197 mg/day group was intermediate to that in the pirfenidone 2403 mg/day and placebo groups. In study 006, the diff erence between groups in FVC change at week 72 was not significant (p=0•501). Mean change in FVC at week 72 was -9•0{\%} (SD 19•6) in the pirfenidone group and -9•6{\%} (19•1) in the placebo group, and the diff erence between groups in predicted FVC change at week 72 was not significant (0•6{\%}, -3•5 to 4•7); however, a consistent pirfenidone eff ect was apparent until week 48 (p=0•005) and in an analysis of all study timepoints (p=0•007). Patients in the pirfenidone 2403 mg/day group had higher incidences of nausea (125 [36{\%}] of 345 vs 60 [17{\%}] of 347), dyspepsia (66 [19{\%}] vs 26 [7{\%}]), vomiting (47 [14{\%}] vs 15 [4{\%}]), anorexia (37 [11{\%}] vs 13 [4{\%}]), photosensitivity (42 [12{\%}] vs 6 [2{\%}]), rash (111 [32{\%}] vs 40 [12{\%}]), and dizziness (63 [18{\%}] vs 35 [10{\%}]) than did those in the placebo group. Fewer overall deaths (19 [6{\%}] vs 29 [8{\%}]) and fewer deaths related to idiopathic pulmonary fibrosis (12 [3{\%}] vs 25 [7{\%}]) occurred in the pirfenidone 2403 mg/day groups than in the placebo groups. Interpretation The data show pirfenidone has a favourable benefit risk profile and represents an appropriate treatment option for patients with idiopathic pulmonary fibrosis.",
author = "Noble, {Paul W.} and Carlo Albera and Bradford, {Williamson Z.} and Ulrich Costabel and {Glassberg Csete}, {Marilyn K} and David Kardatzke and King, {Talmadge E.} and Lisa Lancaster and Sahn, {Steven A.} and Javier Szwarcberg and Dominique Valeyre and {Du Bois}, {Roland M.}",
year = "2011",
month = "5",
day = "21",
doi = "10.1016/S0140-6736(11)60405-4",
language = "English",
volume = "377",
pages = "1760--1769",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9779",

}

TY - JOUR

T1 - Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY)

T2 - Two randomised trials

AU - Noble, Paul W.

AU - Albera, Carlo

AU - Bradford, Williamson Z.

AU - Costabel, Ulrich

AU - Glassberg Csete, Marilyn K

AU - Kardatzke, David

AU - King, Talmadge E.

AU - Lancaster, Lisa

AU - Sahn, Steven A.

AU - Szwarcberg, Javier

AU - Valeyre, Dominique

AU - Du Bois, Roland M.

PY - 2011/5/21

Y1 - 2011/5/21

N2 - Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was designed to confirm the results of a phase 2 study that suggested that pirfenidone, a novel antifibrotic and anti-inflammatory drug, reduces deterioration in lung function in patients with idiopathic pulmonary fibrosis. Methods In two concurrent trials (004 and 006), patients (aged 40-80 years) with idiopathic pulmonary fibrosis were randomly assigned to oral pirfenidone or placebo for a minimum of 72 weeks in 110 centres in Australia, Europe, and North America. In study 004, patients were assigned in a 2:1:2 ratio to pirfenidone 2403 mg/day, pirfenidone 1197 mg/day, or placebo; in study 006, patients were assigned in a 1:1 ratio to pirfenidone 2403 mg/day or placebo. The randomisation code (permuted block design) was computer generated and stratified by region. All study personnel were masked to treatment group assignment until after final database lock. Treatments were administered orally, 801 mg or 399 mg three times a day. The primary endpoint was change in percentage predicted forced vital capacity (FVC) at week 72. Analysis was by intention to treat. The studies are registered with ClinicalTrials.gov, numbers NCT00287729 and NCT00287716. Findings In study 004, 174 of 435 patients were assigned to pirfenidone 2403 mg/day, 87 to pirfenidone 1197 mg/day, and 174 to placebo. In study 006, 171 of 344 patients were assigned to pirfenidone 2403 mg/day, and 173 to placebo. All patients in both studies were analysed. In study 004, pirfenidone reduced decline in FVC (p=0•001). Mean FVC change at week 72 was -8•0% (SD 16•5) in the pirfenidone 2403 mg/day group and -12•4% (18•5) in the placebo group (diff erence 4•4%, 95% CI 0•7 to 9•1); 35 (20%) of 174 versus 60 (35%) of 174 patients, respectively, had a decline of at least 10%. A significant treatment eff ect was noted at all timepoints from week 24 and in an analysis over all study timepoints (p=0•0007). Mean change in percentage FVC in the pirfenidone 1197 mg/day group was intermediate to that in the pirfenidone 2403 mg/day and placebo groups. In study 006, the diff erence between groups in FVC change at week 72 was not significant (p=0•501). Mean change in FVC at week 72 was -9•0% (SD 19•6) in the pirfenidone group and -9•6% (19•1) in the placebo group, and the diff erence between groups in predicted FVC change at week 72 was not significant (0•6%, -3•5 to 4•7); however, a consistent pirfenidone eff ect was apparent until week 48 (p=0•005) and in an analysis of all study timepoints (p=0•007). Patients in the pirfenidone 2403 mg/day group had higher incidences of nausea (125 [36%] of 345 vs 60 [17%] of 347), dyspepsia (66 [19%] vs 26 [7%]), vomiting (47 [14%] vs 15 [4%]), anorexia (37 [11%] vs 13 [4%]), photosensitivity (42 [12%] vs 6 [2%]), rash (111 [32%] vs 40 [12%]), and dizziness (63 [18%] vs 35 [10%]) than did those in the placebo group. Fewer overall deaths (19 [6%] vs 29 [8%]) and fewer deaths related to idiopathic pulmonary fibrosis (12 [3%] vs 25 [7%]) occurred in the pirfenidone 2403 mg/day groups than in the placebo groups. Interpretation The data show pirfenidone has a favourable benefit risk profile and represents an appropriate treatment option for patients with idiopathic pulmonary fibrosis.

AB - Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was designed to confirm the results of a phase 2 study that suggested that pirfenidone, a novel antifibrotic and anti-inflammatory drug, reduces deterioration in lung function in patients with idiopathic pulmonary fibrosis. Methods In two concurrent trials (004 and 006), patients (aged 40-80 years) with idiopathic pulmonary fibrosis were randomly assigned to oral pirfenidone or placebo for a minimum of 72 weeks in 110 centres in Australia, Europe, and North America. In study 004, patients were assigned in a 2:1:2 ratio to pirfenidone 2403 mg/day, pirfenidone 1197 mg/day, or placebo; in study 006, patients were assigned in a 1:1 ratio to pirfenidone 2403 mg/day or placebo. The randomisation code (permuted block design) was computer generated and stratified by region. All study personnel were masked to treatment group assignment until after final database lock. Treatments were administered orally, 801 mg or 399 mg three times a day. The primary endpoint was change in percentage predicted forced vital capacity (FVC) at week 72. Analysis was by intention to treat. The studies are registered with ClinicalTrials.gov, numbers NCT00287729 and NCT00287716. Findings In study 004, 174 of 435 patients were assigned to pirfenidone 2403 mg/day, 87 to pirfenidone 1197 mg/day, and 174 to placebo. In study 006, 171 of 344 patients were assigned to pirfenidone 2403 mg/day, and 173 to placebo. All patients in both studies were analysed. In study 004, pirfenidone reduced decline in FVC (p=0•001). Mean FVC change at week 72 was -8•0% (SD 16•5) in the pirfenidone 2403 mg/day group and -12•4% (18•5) in the placebo group (diff erence 4•4%, 95% CI 0•7 to 9•1); 35 (20%) of 174 versus 60 (35%) of 174 patients, respectively, had a decline of at least 10%. A significant treatment eff ect was noted at all timepoints from week 24 and in an analysis over all study timepoints (p=0•0007). Mean change in percentage FVC in the pirfenidone 1197 mg/day group was intermediate to that in the pirfenidone 2403 mg/day and placebo groups. In study 006, the diff erence between groups in FVC change at week 72 was not significant (p=0•501). Mean change in FVC at week 72 was -9•0% (SD 19•6) in the pirfenidone group and -9•6% (19•1) in the placebo group, and the diff erence between groups in predicted FVC change at week 72 was not significant (0•6%, -3•5 to 4•7); however, a consistent pirfenidone eff ect was apparent until week 48 (p=0•005) and in an analysis of all study timepoints (p=0•007). Patients in the pirfenidone 2403 mg/day group had higher incidences of nausea (125 [36%] of 345 vs 60 [17%] of 347), dyspepsia (66 [19%] vs 26 [7%]), vomiting (47 [14%] vs 15 [4%]), anorexia (37 [11%] vs 13 [4%]), photosensitivity (42 [12%] vs 6 [2%]), rash (111 [32%] vs 40 [12%]), and dizziness (63 [18%] vs 35 [10%]) than did those in the placebo group. Fewer overall deaths (19 [6%] vs 29 [8%]) and fewer deaths related to idiopathic pulmonary fibrosis (12 [3%] vs 25 [7%]) occurred in the pirfenidone 2403 mg/day groups than in the placebo groups. Interpretation The data show pirfenidone has a favourable benefit risk profile and represents an appropriate treatment option for patients with idiopathic pulmonary fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=79956341531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956341531&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(11)60405-4

DO - 10.1016/S0140-6736(11)60405-4

M3 - Article

VL - 377

SP - 1760

EP - 1769

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9779

ER -